Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BionimeTPE:4737 -1.02%68 EV-to-OCF is 53.37 as of Sep. 10, 2026, which is 110% above its 10-year median of 25.46. GuruFocus rates TPE:4737 with a GF Score™ of 68/100 and a GF Value™ of NT$53.87 (Fairly Valued). The stock has 7 warning signs investors should review. Among 850 Medical Devices & Instruments companies, Bionime ranks worse than 91.53% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Bionime's Enterprise Value is NT$6,720 Mil.
Bionime's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was NT$126 Mil. Therefore, Bionime's EV-to-OCF for today is 53.37.
The historical rank and industry rank for Bionime's EV-to-OCF or its related term are showing as below:
TPE:4737'
s EV-to-OCF Range Over the Past 10 Years
Min: 8.09 Med: 25.46 Max: 351.46
Current: 53.61
During the past 13 years, the highest EV-to-OCF of Bionime was 351.46. The lowest was 8.09. And the median was 25.46.
TPE:4737's EV-to-OCF is ranked worse than 91.53% of 850
companies
in the Medical Devices & Instruments industry
Industry Median: 7.875
vs TPE:4737: 53.61
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-10), Bionime's stock price is NT$58.20.
Bionime's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was NT$-4.028. Therefore, Bionime's PE Ratio (TTM) for today is At Loss.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bionime's share price for today is NT$58.20.
Bionime's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bionime EV-to-OCF Related Terms
Bionime EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Bionime's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Bionime's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Bionime's EV-to-OCF falls into.
Bionime's current Enterprise Value is NT$6,720 Mil.
Bionime's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$126 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a EV-to-OCF of 53.37 as of Sep. 10, 2026. This is 110% above median its historical median of 25.46. Over the past decade, Bionime's EV-to-OCF has ranged from 8.09 to 351.46. According to the industry distribution chart, Bionime ranks #778 out of 850 companies in the Medical Devices & Instruments industry, placing it in the top 91.5%.
Is Bionime's EV-to-OCF too high?
Bionime's current EV-to-OCF of 53.37 is 110% above median its 10-year median of 25.46. Over the past 10 years, this metric has ranged from a low of 8.09 to a high of 351.46. The Medical Devices & Instruments industry median EV-to-OCF is 7.88. Bionime's value of 53.37 is 577.7% above this industry median. Based on the distribution chart, Bionime ranks #778 out of 850 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bionime has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's EV-to-OCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #778 out of 850 companies for EV-to-OCF. This places Bionime in the lower half of its industry. The industry median EV-to-OCF is 7.88. Bionime's value of 53.37 is 577.7% above this benchmark. Historically, Bionime's own EV-to-OCF has ranged from 8.09 to 351.46 over the past decade. While the company's 10-year median is 25.46 vs. the industry median of 7.88, Bionime has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.88, based on 850 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionime's current EV-to-OCF of 53.37 is 577.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current EV-to-OCF is 53.37, which is 110% above median its own 10-year median of 25.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$53.87, compared to a current price of NT$58.20 — trading 8% above its estimated fair value. The current EV-to-OCF is 53.37, which is 110% above median its 10-year median of 25.46 and 577.7% above the Medical Devices & Instruments industry median of 7.88. Bionime's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Bionime (TPE:4737), the current EV-to-OCF is 53.37 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be overvalued.
The current stock price of NT$58.20 is trading 8% above its estimated GF Value™ of NT$53.87.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
EV-to-OCF: 53.37 (110% above median its 10-year median of 25.46)
GF Value™: NT$53.87 vs. price of NT$58.20 (8% above fair value)
Industry Position: 577.7% above the Medical Devices & Instruments median (#778 of 850)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
68GF Score
Get the complete analysis for TPE:4737
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
